Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daprodustat vs Darbepoetin Alfa on Forearm Blood Flow in Anemia of CKD
NCT03446612Phase 2Terminated
- Sponsor
- GSK
- Start
- Jan 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daprodustat in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by GSK. Primary endpoint: Change in Forearm Blood Flow Ratio in Response to Acetylcholine at Day 42. Started Jan 2019; status: terminated.
02
Drugs
daprodustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03446612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446612.